Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)11.23m
- Net income in SEK-16.40m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center GoteborgMassans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asarina Pharma AB (publ) | 0.00 | -12.91m | 18.25m | -- | -- | 11.68 | -- | -- | -0.5704 | -0.5704 | 0.00 | 0.069 | 0.00 | -- | -- | -- | -113.04 | -61.28 | -150.47 | -71.81 | -- | -- | -- | -- | -- | -- | 0.3902 | -- | -- | -- | 2.79 | -- | -- | -- |
AegirBio AB | 36.00k | -49.38m | 18.80m | 13.00 | -- | -- | -- | 522.33 | -2.18 | -2.18 | 0.0015 | -0.3413 | 0.0005 | -- | 0.0065 | 2,769.23 | -67.93 | -- | -82.25 | -- | 355.56 | -- | -137,155.60 | -- | 0.5183 | -43.54 | 1.40 | -- | -94.61 | -- | 83.55 | -- | -- | -- |
Lidds AB | 0.00 | -40.21m | 20.47m | 2.00 | -- | 0.7364 | -- | -- | -0.8316 | -0.8316 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -184.54 | -46.33 | -274.93 | -51.61 | -- | -1,934.24 | -- | -3,076.68 | -- | -- | 0.00 | -- | -100.00 | -- | -9.08 | -- | -- | -- |
Cyxone AB | 0.00 | -21.66m | 28.50m | 1.00 | -- | 0.8309 | -- | -- | -0.1497 | -0.1497 | 0.00 | 0.1589 | 0.00 | -- | -- | -- | -50.57 | -66.19 | -57.08 | -72.35 | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -- | -- | 45.87 | -- | -12.69 | -- |
Gabather AB | 0.00 | -9.44m | 30.22m | -- | -- | 48.36 | -- | -- | -0.652 | -0.652 | 0.00 | 0.0331 | 0.00 | -- | -- | -- | -133.71 | -56.57 | -480.99 | -67.36 | -- | -- | -- | -17,298,800.00 | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- |
Fluicell AB | 1.86m | -29.02m | 31.79m | 12.00 | -- | 1.84 | -- | 17.06 | -0.1936 | -0.1936 | 0.0109 | 0.0527 | 0.0796 | 0.5404 | 1.74 | 109,588.20 | -123.93 | -87.55 | -164.04 | -126.02 | 20.93 | 72.97 | -1,557.49 | -650.23 | 3.02 | -- | 0.00 | -- | 2.68 | 22.18 | -22.90 | -- | -- | -- |
Elicera Therapeutics AB | 11.23m | -16.40m | 32.99m | 2.00 | -- | 1.13 | -- | 2.94 | -0.8289 | -0.8289 | 0.5677 | 0.8291 | 0.2936 | -- | 8.13 | 5,615,030.00 | -42.88 | -40.06 | -66.66 | -49.74 | -- | -- | -146.02 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
Lipigon Pharmaceuticals AB | 16.41m | -12.13m | 34.77m | -- | -- | 1.22 | -- | 2.12 | -0.4662 | -0.4662 | 0.3201 | 0.225 | 0.7388 | -- | 14.81 | -- | -54.60 | -314.67 | -75.05 | -426.49 | -- | -- | -73.91 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
Modus Therapeutics Holding AB | 0.00 | -14.96m | 37.20m | 2.00 | -- | 2.55 | -- | -- | -0.7495 | -0.7495 | 0.00 | 0.4056 | 0.00 | -- | -- | 0.00 | -128.10 | -141.06 | -502.76 | -278.44 | -- | -- | -- | -- | -- | -11.79 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
Circio Holding ASA | 123.74k | -111.40m | 38.38m | 11.00 | -- | -- | -- | 310.14 | -16.75 | -16.75 | 0.0181 | -12.89 | 0.0019 | -- | 0.0072 | 11,181.82 | -172.29 | -46.58 | -- | -53.40 | -- | -- | -90,029.27 | -6,902.00 | -- | -9.82 | 7.73 | -- | -98.77 | 35.43 | 74.42 | -- | -- | -- |
Oncozenge AB | 0.00 | -15.90m | 40.88m | -- | -- | 2.19 | -- | -- | -1.36 | -1.36 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -55.57 | -- | -60.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
Veg of Lund AB (publ) | 4.82m | -19.91m | 46.22m | 7.00 | -- | 1.10 | -- | 9.60 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
Scandion Oncology A/S | 0.00 | -61.02m | 48.44m | 4.00 | -- | 1.00 | -- | -- | -1.52 | -1.52 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -63.25 | -45.09 | -76.67 | -52.65 | -- | -- | -- | -- | -- | -- | 0.0158 | -- | -- | -- | 48.89 | -- | -- | -- |